Educational information, not medical advice — ask your doctor or midwife.
Gamma-oryzanol is not a single molecule but a family of closely related compounds found in the bran layer of rice. Each one is a molecule of ferulic acid — a well-studied plant antioxidant — chemically joined to a plant sterol or triterpene alcohol. The main members are cycloartenyl ferulate, 24-methylenecycloartanyl ferulate, campesteryl ferulate and β-sitosteryl ferulate. It is what gives unrefined rice bran oil much of its oxidative stability, and small amounts also occur in corn and barley bran.
Its history is unusual for a natural product. Rather than coming out of a herbal tradition, gamma-oryzanol was isolated in Japan in the 1950s and became a licensed pharmaceutical there, prescribed for high cholesterol and for the vague cluster of menopausal and "autonomic imbalance" symptoms that Japanese medicine treats as a category. It is also widely used in China as guweisu. That long regulatory history is often mistaken for a strong evidence base; the trials behind it are mostly small and dated.
In the West it took a different path, arriving in the 1980s as a bodybuilding supplement promoted as a natural anabolic. That claim was tested and did not hold up. What remains genuinely interesting is its antioxidant chemistry, its modest effect on cholesterol absorption, and its very good tolerability.
Two mechanisms are reasonably well supported in laboratory and animal work. First, the sterol part of the molecule appears to interfere with cholesterol absorption in the gut and to increase the conversion of cholesterol into bile acids, which is the same broad route by which plant sterols lower LDL. Second, the ferulic acid part is an effective free-radical scavenger and UV absorber, which is why gamma-oryzanol is used as an antioxidant in cooking oils and in sunscreens. Its use in Japan for menopausal flushing and autonomic symptoms is attributed to an effect on hypothalamic and pituitary signalling, but this rests largely on old animal work rather than on human data. A practical limitation runs through all of it: oral absorption is poor, so the amount reaching the bloodstream from a capsule is small.
Capsules and tablets standardised to 100–300 mg of gamma-oryzanol are the usual supplement form and match what was used in the small clinical studies. Rice bran oil is the everyday dietary source — unrefined or lightly refined oil retains far more gamma-oryzanol than heavily refined oil, roughly a few hundred milligrams per 100 g, though refining strips much of it out. Stabilised rice bran powder supplies gamma-oryzanol along with fibre, tocotrienols and B vitamins, and is a reasonable whole-food option. Because the compounds are fat-soluble and poorly absorbed, capsules are best taken with a meal containing fat. Topical formulations use it as an antioxidant and UV-absorbing ingredient in creams and sunscreens; that is a cosmetic application, not a systemic one.
Gamma-oryzanol was first isolated from rice bran oil by Japanese chemists in the 1950s, and by the early 1960s Japan had approved it as a prescription medicine. It has been used there for hyperlipidaemia, for climacteric (menopausal) complaints, and for stress-related stomach and bowel symptoms grouped under autonomic dysfunction. China adopted it under the name guweisu for similar indications. Rice bran itself has a much older place as food and folk remedy across East and South Asia, but the isolated compound is a twentieth-century product. Its Western career began around 1985, when it was marketed to weightlifters as a legal anabolic on the strength of animal studies; a controlled trial in resistance-trained men in the 1990s found no effect on hormones or strength beyond training itself, and the claim quietly faded, though it still appears on labels.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.